FDA Inspections for Sterile Compounders: The Impact of DQSA
Thursday, Oct. 29 at 11 a.m.
The Food and Drug Administration is directing its inspectors to find one ... just one .. instance of an office-use compound to justify allegations that a compounding pharmacist isn't eligible for the exemptions provided for within section 503A of the Food, Drug and Cosmetic Act. And without those exemptions any compounder can then be held to Current Good Manufacturing Standards. Understand the approach and the areas which are absolutely critical to FDA inspectors. Join this live online webinar accredited for 1.0 contact hour or (0.10 CEU). $45 for AzPA members, $70 for non-members.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063